Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: "Samuel Waxman" Clear advanced filters

  • Synthetic lethality has emerged as a novel approach to treat cancer. Inhibitors of poly (ADP-ribose) polymerase, a target that has synthetic lethality withBRCAmutations, have already shown promise in clinical trials. The authors of this Review describe the clinical application of synthetic lethality for patients with breast cancer, and discuss biomarkers that can be used to select patients who will respond to this therapy. Other potential genes that could be involved in synthetic lethality, and are thus new targets, are also explored.

    • Farah L. Rehman
    • Christopher J. Lord
    • Alan Ashworth
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 7, P: 718-724

  • DNA repair as a therapeutic target has received considerable attention in the treatment of non-small-cell lung cancer (NSCLC). In this Review, Postel-Vinay et al. discuss how optimizing treatment of NSCLC according to DNA-repair biomarkers, such as ERCC1, BRCA1 or RRM1, may aid clinical decision making and improve the outcome of patients with NSCLC.

    • Sophie Postel-Vinay
    • Elsa Vanhecke
    • Jean-Charles Soria
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 9, P: 144-155

  • Tankyrases — members of the poly(ADP-ribose) polymerase (PARP) protein superfamily — are involved in diverse cellular processes, including WNT signalling and telomere maintenance. Here, the authors describe the biology of tankyrases and the discovery of tankyrase-specific inhibitors, which could have broad clinical utility. The challenges that lie ahead for the clinical development of PARP family inhibitors in general are also examined.

    • Jenna L. Riffell
    • Christopher J. Lord
    • Alan Ashworth
    Reviews
    Nature Reviews Drug Discovery
    Volume: 11, P: 923-936

  • Inhibitors of poly(ADP-ribose)polymerase (PARP) have shown promise as therapeutic agents for the treatment of ovarian cancers with mutations inBRCA1 or BRCA2. By exploiting the synthetic lethal interaction that exists between PARP inhibition and BRCA mutations, these agents specifically kill cancer cells by targeting their DNA repair system. The authors of this Review describe the importance of BRCAmutations for the efficacy of PARP inhibitors. They also discuss the preclinical and clinical trial results of PARP inhibitors, the challenges related to the use of these agents, and future directions.

    • Susana Banerjee
    • Stan B. Kaye
    • Alan Ashworth
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 7, P: 508-519